DAT

The dopamine transporter (DAT) is a membrane protein found on the surface of dopamine-releasing neurons. Its job is to end a dopamine signal: after dopamine is released into the synapse and binds to receptors on the receiving cell, DAT pumps the leftover dopamine back into the releasing neuron, clearing the gap and making that dopamine available for reuse.

Without this cleanup mechanism, dopamine would accumulate in the synapse and keep signalling. DAT is therefore a key regulator of how long and how strongly dopamine acts — and because dopamine is central to motivation, reward, and movement, DAT sits at the heart of how stimulants and several other drugs produce their effects.

How it works · its role

DAT works by a process called reuptake: it binds dopamine molecules in the synaptic cleft and transports them back across the presynaptic membrane, against a concentration gradient, using the energy of a sodium ion gradient to do so. The process is fast enough that under normal conditions dopamine signals are brief and tightly localised.

Drugs interact with DAT in two distinct ways. Some — cocaine being the canonical example — bind to DAT and block it, preventing reuptake without triggering release. Dopamine then accumulates in the synapse, prolonging and amplifying the signal. Others, including amphetamines, do something more forceful: they enter the neuron via DAT and reverse its direction, actively pumping dopamine out into the synapse rather than simply blocking the drain.

These two mechanisms produce overlapping but not identical effects. Blockers depend on ongoing dopamine release to work; releasers generate a surge of their own.

Relevance to substances & effects

DAT is the primary site of action for cocaine, which blocks it rapidly and produces a short-lived but intense dopamine surge in reward-related brain areas, particularly the nucleus accumbens. The brevity of cocaine's effect is partly a consequence of how quickly the block clears.

Amphetamines — including dextroamphetamine and methamphetamine — work through DAT as a reversed transporter, driving larger and more sustained dopamine efflux. This accounts for their longer duration and, at high doses, their greater potential for releasing dopamine beyond what ordinary neuron firing would produce.

Methylphenidate, used clinically for ADHD, is also a DAT blocker, though its pharmacokinetics differ from cocaine in ways that are thought to reduce its reinforcing intensity at therapeutic doses.

MDMA acts on DAT as well, but its primary target is the SERT (SERT); the dopamine component contributes to the stimulant and euphoric qualities without dominating the overall profile.

Because DAT controls the strength and duration of dopamine signalling in reward circuits, substances that block or reverse it are strongly associated with reinforcing subjective effects — euphoria, energy, and heightened motivation — and with the neuroadaptations that underlie stimulant dependence.